Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $5.20M | $2.23M | $6.59M | $109M |
| Revenue growth | — | — | — | -57.0% | 194.8% | 1556.8% |
| Operating income | -$53.9M | -$94.9M | -$134M | -$147M | -$138M | -$17.3M |
| Operating margin | — | — | -2574.2% | -6556.9% | -2096.5% | -15.8% |
| Net income | -$53.6M | -$95.8M | -$131M | -$137M | -$127M | -$9.58M |
| Net margin | — | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (diluted) | -$7.16 | -$2.96 | -$2.96 | -$2.30 | -$1.61 | -$0.14 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$41.3M | -$89.0M | $14.1M | -$88.3M | -$110M | -$104M |
| Capital expenditures | $9.82M | $45.0M | $30.6M | $13.7M | $154K | $848K |
| Free cash flow | -$51.1M | -$134M | -$16.6M | -$102M | -$110M | -$105M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.2M | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Total assets | $107M | $437M | $487M | $361M | $353M | $224M |
| Total liabilities | $33.4M | $41.1M | $184M | $176M | $192M | $64.8M |
| Long-term debt | $9.64M | $8.90M | $3.74M | — | — | — |
| Shareholders' equity | -$106M | $396M | $303M | $185M | $161M | $159M |
| Retained earnings | -$292M | -$388M | -$519M | -$656M | -$782M | -$792M |
| Shares (wtd avg diluted) | 7.48M | 32.4M | 32.4M | 59.3M | 78.6M | 86.6M |
Every figure is extracted from Century Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.